EG24000A - N-(3-ethynylphenylamino) 6,7-bis (2-methoxye-thoxy) -4-quinazolinamine mesylate anhydrate and monohydrate - Google Patents

N-(3-ethynylphenylamino) 6,7-bis (2-methoxye-thoxy) -4-quinazolinamine mesylate anhydrate and monohydrate

Info

Publication number
EG24000A
EG24000A EG48299A EG48299A EG24000A EG 24000 A EG24000 A EG 24000A EG 48299 A EG48299 A EG 48299A EG 48299 A EG48299 A EG 48299A EG 24000 A EG24000 A EG 24000A
Authority
EG
Egypt
Prior art keywords
methoxye
ethynylphenylamino
thoxy
monohydrate
bis
Prior art date
Application number
EG48299A
Other languages
English (en)
Inventor
Douglas J Allen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of EG24000A publication Critical patent/EG24000A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG48299A 1998-04-29 1999-04-29 N-(3-ethynylphenylamino) 6,7-bis (2-methoxye-thoxy) -4-quinazolinamine mesylate anhydrate and monohydrate EG24000A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
EG24000A true EG24000A (en) 2008-03-19

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
EG48299A EG24000A (en) 1998-04-29 1999-04-29 N-(3-ethynylphenylamino) 6,7-bis (2-methoxye-thoxy) -4-quinazolinamine mesylate anhydrate and monohydrate

Country Status (42)

Country Link
EP (1) EP1076652B1 (xx)
JP (1) JP4652569B2 (xx)
KR (1) KR100668412B1 (xx)
CN (2) CN1298396A (xx)
AP (1) AP1252A (xx)
AR (1) AR018201A1 (xx)
AT (1) ATE295839T1 (xx)
AU (1) AU759691C (xx)
BR (1) BR9910025A (xx)
CA (1) CA2330447C (xx)
CO (1) CO5060467A1 (xx)
CZ (1) CZ298230B6 (xx)
DE (1) DE69925366T2 (xx)
DZ (1) DZ2777A1 (xx)
EA (1) EA002836B1 (xx)
EG (1) EG24000A (xx)
ES (1) ES2238825T3 (xx)
GT (1) GT199900063A (xx)
HK (1) HK1037180A1 (xx)
HN (1) HN1999000057A (xx)
HU (1) HU227569B1 (xx)
ID (1) ID27198A (xx)
IL (1) IL139172A0 (xx)
MA (1) MA26624A1 (xx)
ME (1) MEP42008A (xx)
MX (1) MXPA00010610A (xx)
MY (1) MY136033A (xx)
NO (1) NO317301B1 (xx)
NZ (1) NZ508154A (xx)
OA (1) OA11769A (xx)
PA (1) PA8471001A1 (xx)
PE (1) PE20000441A1 (xx)
PL (1) PL196940B1 (xx)
RS (1) RS50081B (xx)
SA (1) SA99200216B1 (xx)
TN (1) TNSN99079A1 (xx)
TR (1) TR200003166T2 (xx)
TW (1) TWI248437B (xx)
UA (1) UA60363C2 (xx)
UY (1) UY26099A1 (xx)
WO (1) WO1999055683A1 (xx)
ZA (1) ZA992972B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
ES2293251T3 (es) 2003-06-10 2008-03-16 F. Hoffmann-La Roche Ag Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno.
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
ATE497762T1 (de) 2004-12-30 2011-02-15 Bioresponse Llc Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
US8586621B2 (en) 2006-10-27 2013-11-19 Michael A. Zeligs Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
CA2682013C (en) * 2007-04-04 2015-06-30 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
DK0817775T3 (da) * 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
HN1999000057A (es) 1999-09-29
EA002836B1 (ru) 2002-10-31
GT199900063A (es) 2000-10-20
HK1037180A1 (en) 2002-02-01
MEP42008A (en) 2011-02-10
NZ508154A (en) 2003-07-25
CZ298230B6 (cs) 2007-08-01
CA2330447C (en) 2009-06-30
MXPA00010610A (es) 2002-07-02
CO5060467A1 (es) 2001-07-30
EA200001112A1 (ru) 2001-04-23
NO20005453D0 (no) 2000-10-27
NO20005453L (no) 2000-12-20
HUP0101818A1 (hu) 2002-03-28
ES2238825T3 (es) 2005-09-01
TNSN99079A1 (fr) 2005-11-10
MY136033A (en) 2008-07-31
CN1298396A (zh) 2001-06-06
RS50081B (sr) 2009-01-22
TWI248437B (en) 2006-02-01
PL343766A1 (en) 2001-09-10
JP4652569B2 (ja) 2011-03-16
KR20010078710A (ko) 2001-08-21
AR018201A1 (es) 2001-10-31
AP9901523A0 (en) 1999-06-30
BR9910025A (pt) 2000-12-26
NO317301B1 (no) 2004-10-04
PL196940B1 (pl) 2008-02-29
AU759691C (en) 2004-04-29
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
JP2002513009A (ja) 2002-05-08
PA8471001A1 (es) 2000-09-29
ID27198A (id) 2001-03-08
EP1076652A1 (en) 2001-02-21
SA99200216B1 (ar) 2006-06-04
AU2850999A (en) 1999-11-16
ZA992972B (en) 2000-10-30
CZ20003974A3 (en) 2001-05-16
EP1076652B1 (en) 2005-05-18
AU759691B2 (en) 2003-04-17
ATE295839T1 (de) 2005-06-15
IL139172A0 (en) 2001-11-25
CA2330447A1 (en) 1999-11-04
KR100668412B1 (ko) 2007-01-12
HU227569B1 (en) 2011-08-29
AP1252A (en) 2004-02-25
OA11769A (en) 2005-07-25
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
WO1999055683A1 (en) 1999-11-04
DE69925366D1 (de) 2005-06-23
PE20000441A1 (es) 2000-05-23
MA26624A1 (fr) 2004-12-20
TR200003166T2 (tr) 2001-02-21
HUP0101818A3 (en) 2002-05-28
UA60363C2 (uk) 2003-10-15
CN101219999A (zh) 2008-07-16

Similar Documents

Publication Publication Date Title
EG24000A (en) N-(3-ethynylphenylamino) 6,7-bis (2-methoxye-thoxy) -4-quinazolinamine mesylate anhydrate and monohydrate
EP1066039A4 (en) SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
GB2332993B (en) Fully integrated ballast ic
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
HUP0203430A3 (en) Quinazolinones and their use
DE69940128D1 (de) Chinazolin- und Pyridopyrimidinderivate
DE69833751D1 (de) IN POSITION 5 UND 6 MODIFIZIERTE GONADOTROPIN FREISETZENDES HORMON (GnRH)-ANTAGONISTEN
HUP0300205A3 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
DK0901487T3 (da) 2,3,6-trisubstituerede 4(3H)-quinazolinoner
HUP0102831A2 (hu) Új, helyi érzéstelenítő vegyületek és azok alkalmazásai
DE69903961D1 (de) Muscarinagonisten und antagonisten
NO20004274D0 (no) Proteaseaktivert reseptor 4 og anvendelse derav
DE59903751D1 (de) 2',2'-difluornucleoside zur immunosuppressiven therapie und kombinationspräparate
PL348668A1 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
HUP0103166A3 (en) Carbamate and urea compositions and neurotrophic uses
ATE282015T1 (de) Rheologieänderung und rheologiemodifiziermittel
GB9820014D0 (en) Receptor antagonists and uses thereof
ZA985326B (en) Aminospiropiperidine quinazoline derivatives
GB2392159B (en) Endo-ß-1, 4, xylanase and uses thereof
EP1139972A4 (en) DIHYDROPYRIMIDINES AND THEIR USES
MXPA02005775A (es) Moleculas ralacionadas con el antagonista del receptor de la interleucina-1 y usos de las mismas.
DE69839570D1 (de) Halbleiteranordnung und dessen betriebsverfahren
GB9603049D0 (en) Quinazoline derivatives
GB9700695D0 (en) Quinazoline derivatives
GB9606865D0 (en) Quinazoline derivatives